Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Drop in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 272,000 shares, a decline of 68.8% from the January 15th total of 872,900 shares. Based on an average daily trading volume, of 142,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.5% of the company’s shares are short sold.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Nautilus Biotechnology during the 4th quarter valued at $28,000. SG Americas Securities LLC grew its stake in Nautilus Biotechnology by 56.3% in the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC raised its holdings in Nautilus Biotechnology by 45.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after purchasing an additional 8,888 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Nautilus Biotechnology during the third quarter valued at $67,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Nautilus Biotechnology by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after buying an additional 9,404 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Price Performance

NAUT remained flat at $1.60 during midday trading on Wednesday. The company’s stock had a trading volume of 161,159 shares, compared to its average volume of 116,359. Nautilus Biotechnology has a fifty-two week low of $1.56 and a fifty-two week high of $3.10. The firm has a 50 day moving average price of $1.84 and a two-hundred day moving average price of $2.33. The company has a market cap of $200.90 million, a PE ratio of -2.86 and a beta of 1.21.

Analyst Ratings Changes

Separately, The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their price target for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.